LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
LENZ Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.30+0.03 (+0.92%)
Close on Oct 19, 2026
- Market cap
- $103.54M
- P/E (TTM)
- –
- Dividend yield
- –
LENZ Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | LENZ Therapeutics | Industry median |
|---|---|---|
| Market Cap | $103.69M | $164.85M |
| Enterprise Value | -$116.31M | $87.06M |
| PS Ratio | 4.83 | 3.60 |
| PB Ratio | 0.47 | 2.03 |
| P/TBV Ratio | 0.47 | 2.31 |
Enterprise value
| Measure | LENZ Therapeutics | Industry median |
|---|---|---|
| EV / Sales | -5.42 | 2.43 |
Income (trailing twelve months)
| Measure | LENZ Therapeutics | Industry median |
|---|---|---|
| Revenue | $21.48M | $57.94M |
| Operating Income | -$135.66M | -$21.44M |
| Net Income | -$126.00M | -$22.46M |
| EBITDA | -$135.20M | -$16.91M |
| EPS (Diluted) | -$4.08 | -$0.83 |
Margins
| Measure | LENZ Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -631.7% | -44.5% |
| Profit Margin | -586.7% | -39.2% |
| EBITDA Margin | -629.6% | -31.3% |
| FCF Margin | -532.8% | -8.85% |
Returns
| Measure | LENZ Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -59.2% | -53.1% |
| Return on Assets (ROA) | -55.5% | -41.0% |
| Return on Capital Employed (ROCE) | -61.8% | -37.8% |
Growth
| Measure | LENZ Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 329.5% | 6.01% |
Balance sheet
| Measure | LENZ Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $220.00M | $62.42M |
| Net Cash (Debt) | $220.00M | $15.68M |
| Net Cash Per Share | $7.00 | $0.66 |
| Equity (Book Value) | $219.26M | $48.79M |
| Book Value Per Share | $6.98 | $1.36 |
| Tangible Book Value | $219.26M | $23.06M |
| Working Capital | $216.07M | $75.77M |
Financial position
| Measure | LENZ Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 13.55 | 3.30 |
| Quick Ratio | 12.81 | 2.39 |
Cash flow (trailing twelve months)
| Measure | LENZ Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$113.91M | -$12.35M |
| Capital Expenditures | -$511.00K | -$1.06M |
| Free Cash Flow | -$114.42M | -$20.28M |
| FCF Per Share | -$3.64 | -$0.42 |
Efficiency
| Measure | LENZ Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.09 | 0.38 |
| Revenue Per Employee | $141.28K | $398.96K |
| Profits Per Employee | -$828.96K | -$703.34K |
| Employee Count | 152 | 74 |
Dividends and yields
| Measure | LENZ Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -121.5% | -22.7% |
| FCF Yield | -110.3% | -9.07% |
Shares
| Measure | LENZ Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 31,420,300 | 58,179,650 |
| Shares Change (YoY) | 10.9% | 11.1% |
| Shares Change (QoQ) | 0.20% | 0.54% |
| Float | 25,108,700 | 49,173,100 |
| Shares Held by Insiders | 20.1% | 11.6% |
| Shares Held by Institutions | 110.5% | 59.4% |
Scores
| Measure | LENZ Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 1.11 | -0.24 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from LENZ Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.